Attainment of target Rifampicin (cas 13292-46-1) concentrations in cerebrospinal fluid during treatment of tuberculous meningitis
-
Add time:07/19/2019 Source:sciencedirect.com
ObjectiveThere is considerable uncertainty regarding the optimal use of Rifampicin (cas 13292-46-1) for the treatment of tuberculous (TB) meningitis. A pharmacokinetic modeling and simulation study of rifampicin concentrations in cerebrospinal fluid (CSF) during TB meningitis treatment was performed in this study.
We also recommend Trading Suppliers and Manufacturers of Rifampicin (cas 13292-46-1). Pls Click Website Link as below: cas 13292-46-1 suppliers
Prev:The optimization of methadone dosing whilst treating with Rifampicin (cas 13292-46-1): A pharmacokinetic modeling study
Next:Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis) - 【Back】【Close 】【Print】【Add to favorite 】